ARCAPTA NEOHALER Drug Patent Profile

Which patents cover Arcapta Neohaler, and when can generic versions of Arcapta Neohaler launch?

Arcapta Neohaler is a drug marketed by Novartis and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-seven patent family members in thirty-one countries.

The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.

DrugPatentWatch^® Generic Entry Outlook for Arcapta Neohaler

Arcapta Neohaler was eligible for patent challenges on July 1, 2015.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 11, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ARCAPTA NEOHALER

International Patents:	37
US Patents:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ARCAPTA NEOHALER

ARCAPTA NEOHALER is protected by one US patents.

This potential generic entry date is based on patent 8,479,730.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	ARCAPTA NEOHALER	indacaterol maleate	POWDER;INHALATION	022383-001	Jul 1, 2011		DISCN	Yes	No	8,479,730		Y

International Patents for ARCAPTA NEOHALER

See the table below for patents covering ARCAPTA NEOHALER around the world.

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2006143840	ИНГАЛЯТОР
Turkey	200103497
Morocco	28612	DISPOSITIF D'INHALATION
Japan	2007536962

Supplementary Protection Certificates for ARCAPTA NEOHALER

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1267866	92393	Luxembourg		PRODUCT NAME: GLYCOPYRRONIUM OU UN SEL DE CELUI-CI, PLUS PARTICULIEREMENT LE SEL BROMURE, COMBINE A INDACATEROL OU UN SEL DE CELUI-CI, PLUS PARTICULIEREMENT LE SEL MALEATE. FIRST REGISTRATION: 20130923
1183240	7/2010	Austria		PRODUCT NAME: INDACATEROL UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/09/593/001-010 20091130
1183240	SPC009/2010	Ireland		SPC009/2010: 20100813, EXPIRES: 20241129
1267866	132014902244065	Italy		PRODUCT NAME: INDACATEROLO O UN SUO SALE, IN PARTICOLARE IL SALE MALEATO, E GLICOPIRRONIO O UN SUO SALE, IN PARTICOLARE IL SALE BROMURO, IN ASSOCIAZIONE(ULTIBRO BREEZHALER); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/862, 20130919

Investment Scenario and Fundamentals Analysis for ARCAPTA NEOHALER

Last updated: February 20, 2026

What Is ARCAPTA NEOHALER?

ARCAPTA NEOHALER (indacaterol maleate inhalation powder) is a long-acting beta-2 adrenergic receptor agonist (LABA) approved for the management of chronic obstructive pulmonary disease (COPD). It is marketed by Novartis and is delivered via a dry powder inhaler.

Market Position and Revenue Dynamics

Market Size and Growth

The global COPD market was valued at approximately USD 18 billion in 2022, expected to grow at a compound annual growth rate (CAGR) of 4.2% through 2030 ([2]).

Key Competitors

ARCAPTA competes primarily with:

• Brovana (arformoterol) by Teva
• Stiolto Respimat (tiotropium bromide + olodaterol) by Boehringer Ingelheim
• Striverdi Respimat (olodaterol) by Boehringer Ingelheim

Sales and Market Share

In 2022, ARCAPTA generated USD 500 million in global sales, representing approximately 2.8% of the COPD inhaler market. It was the second-highest selling LABA after indacaterol-based formulations by competitors, and sales are projected to increase at a CAGR of 5% over the next five years ([1]).

Pricing Dynamics

Average wholesale price (AWP) for ARCAPTA is approximately USD 300 per inhaler, with patients typically using one inhaler per month. Pricing is competitive but faces pressure from generics and biosimilars, especially in Europe and emerging markets.

Regulatory and Patent Landscape

Patent Status

Patent protection for ARCAPTA in key markets extends to 2027. Novartis holds patents covering the formulation and delivery device, providing exclusivity during this period.

Regulatory Approvals

ARCAPTA received FDA approval in 2012 for COPD treatment and is approved by EMA since 2011. No major regulatory hurdles reported, but future generic entry depends on patent expiry and market dynamics.

R&D and Pipeline Considerations

Though ARCAPTA itself has not received recent reformulation upgrades, Novartis invests in inhaler technology enhancements and combination therapies. Pipeline developments include fixed-dose combinations that may capture additional market share, though none are currently marketed.

Financial and Investment Outlook

Revenue Trends

ARCAPTA's revenue growth is driven by increased COPD prevalence and aging populations. The drug's steady market penetration is offset by patent expirations in 2027, which could lead to sales erosion if biosimilars or generics enter the market.

Market Risks and Opportunities

Risks include:

• Patent expiry leading to generic competition.
• Price erosion from competitive products and health policy reforms.
• Slow adoption in emerging markets due to reimbursement barriers.

Opportunities include:

• Expansion into Asia-Pacific regions where COPD prevalence rises.
• Development of combination therapies with other COPD treatments.
• Technological innovations in inhaler devices improving adherence.

Investment Considerations

For stakeholders, ARCAPTA's investment prospects hinge on patent protections, market expansion, and pipeline innovations. The expiration in 2027 prompts focus on early indications of biosimilar competition or patent challenges.

Conclusion

ARCAPTA NEOHALER maintains a significant, though niche, position within the COPD inhaler market. Its growth is tied to broader demographic trends, patent protections, and competitive dynamics. The upcoming patent expiry in 2027 requires monitoring, as generic entry could pressure sales and margins.

Key Takeaways

• ARCAPTA generated USD 500 million in 2022 sales, with steady growth projections.
• Patent protection extends to 2027, after which biosimilar competition may intensify.
• Pricing remains competitive, but price erosion remains a risk.
• Market expansion hinges on healthcare adoption in emerging markets.
• Development of combination therapies and device innovations represents growth avenues.

FAQs

1. When does the patent for ARCAPTA expire?
Patent protection extends to 2027 in key markets, after which biosimilar competition is likely.

2. What are the primary competitors of ARCAPTA?
Stiolto Respimat, Striverdi Respimat, and Brovana are the main competitors, each offering similar COPD treatments.

3. How is ARCAPTA priced compared to competitors?
Its AWP is around USD 300 per inhaler, aligning with market averages for LABA inhalers but facing pressure from generics.

4. Are there any upcoming regulatory challenges for ARCAPTA?
No significant current regulatory hurdles are reported; future challenges may come post-patent expiration.

5. What growth strategies are Novartis pursuing with ARCAPTA?
Expanding into emerging markets, developing combination inhalers, and refining device technology are key focus areas.

---

References

1. IQVIA. (2023). Global COPD inhaler sales data.
2. Fortune Business Insights. (2023). Chronic Obstructive Pulmonary Disease Market Size, Share & Industry Trends.